Who Buys Erlotinib from India — 144 Importers Behind a $2.7M Market

The 144 buyers of Erlotinib imported from India can be categorized into several segments:

1. Distributors: Entities that purchase Erlotinib in bulk to supply to various healthcare providers. For instance, ATLANTA MEDICARE CO.LTD in Thailand, the top buyer with imports totaling $0.24 million, likely operates as a distributor, given the substantial volume of their purchases.

2. Hospital Groups: Large healthcare institutions procuring Erlotinib for patient treatment. While specific hospital groups are not identified in the top 10 buyers, it's common for such entities to source medications directly from manufacturers or authorized distributors.

3. Retail Chains: Pharmacy chains that stock Erlotinib for retail sale. WIN PHARMACY CO LTD in Myanmar, with imports totaling $0.09 million, exemplifies this segment, indicating a focus on making Erlotinib accessible to the general public.

4. Government Procurement: Government agencies or international organizations like UNICEF and the Global Fund that procure Erlotinib for public health initiatives. The data does not specify such buyers among the top 10; however, these entities typically engage in large-scale, tender-based purchasing to supply public healthcare facilities.

5. Re-exporters: Companies that import Erlotinib with the intent to export it to other markets. The available data does not clearly identify re-exporters among the top buyers.

6. Contract Manufacturers: Firms that import Erlotinib as raw material for further processing or formulation. The data does not indicate the presence of contract manufacturers among the top 10 buyers.

Typical buying behaviors vary across these segments. Distributors and retail chains often place regular, moderate to large orders to maintain consistent supply chains. Hospital groups may order based on patient demand, leading to variable order sizes. Government procurement agencies usually engage in bulk purchasing through tenders, resulting in large, infrequent orders.

For the top five importing countries of Erlotinib from India, the import regulations are as follows:

The demand for Erlotinib in importing countries is primarily driven by the prevalence of non-small cell lung cancer (NSCLC), for which Erlotinib is a standard treatment. According to the World Health Organization (WHO), cancer is the second leading cause of death globally, with lung cancer being the most common type. The inclusion of Erlotinib in the WHO Model List of Essential Medicines underscores its importance in cancer treatment.

Government healthcare programs and the expansion of universal health coverage in many countries have increased access to essential medicines like Erlotinib. The WHO's Essential Medicines List serves as a guide for countries to develop their national lists, facilitating procurement and distribution. Tender-based purchasing by government agencies and international organizations ensures a steady demand for Erlotinib, as these entities aim to provide affordable and effective cancer treatments to their populations. (who.int)

The 144 buyers of Erlotinib imported from India can be categorized into several segments:

1. Distributors: Entities that purchase Erlotinib in bulk to supply to various healthcare providers. For instance, ATLANTA MEDICARE CO.LTD in Thailand, the top buyer with imports totaling $0.24 million, likely operates as a distributor, given the substantial volume of their purchases.

2. Hospital Groups: Large healthcare institutions procuring Erlotinib for patient treatment. While specific hospital groups are not identified in the top 10 buyers, it's common for such entities to source medications directly from manufacturers or authorized distributors.

3. Retail Chains: Pharmacy chains that stock Erlotinib for retail sale. WIN PHARMACY CO LTD in Myanmar, with imports totaling $0.09 million, exemplifies this segment, indicating a focus on making Erlotinib accessible to the general public.

4. Government Procurement: Government agencies or international organizations like UNICEF and the Global Fund that procure Erlotinib for public health initiatives. The data does not specify such buyers among the top 10; however, these entities typically engage in large-scale, tender-based purchasing to supply public healthcare facilities.

5. Re-exporters: Companies that import Erlotinib with the intent to export it to other markets. The available data does not clearly identify re-exporters among the top buyers.

6. Contract Manufacturers: Firms that import Erlotinib as raw material for further processing or formulation. The data does not indicate the presence of contract manufacturers among the top 10 buyers.

Typical buying behaviors vary across these segments. Distributors and retail chains often place regular, moderate to large orders to maintain consistent supply chains. Hospital groups may order based on patient demand, leading to variable order sizes. Government procurement agencies usually engage in bulk purchasing through tenders, resulting in large, infrequent orders.

For the top five importing countries of Erlotinib from India, the import regulations are as follows:

The demand for Erlotinib in importing countries is primarily driven by the prevalence of non-small cell lung cancer (NSCLC), for which Erlotinib is a standard treatment. According to the World Health Organization (WHO), cancer is the second leading cause of death globally, with lung cancer being the most common type. The inclusion of Erlotinib in the WHO Model List of Essential Medicines underscores its importance in cancer treatment.

Government healthcare programs and the expansion of universal health coverage in many countries have increased access to essential medicines like Erlotinib. The WHO's Essential Medicines List serves as a guide for countries to develop their national lists, facilitating procurement and distribution. Tender-based purchasing by government agencies and international organizations ensures a steady demand for Erlotinib, as these entities aim to provide affordable and effective cancer treatments to their populations. (who.int)